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Various associations between serum vitamin D levels and skin cancer have been
reported. In this issue, van der Pols et al. observed that baseline 25-hydro-
xyvitamin D (25OHD) levels above 75nmol/L were associated with an increased
incidence of basal cell carcinoma and melanoma, and a nonstatistically significant
decreased incidence of squamous cell carcinoma. Complex factors including sun
exposure, skin phototype, and anticarcinogenic and procarcinogenic effects of
vitamin D are potential causes of the observed associations.
Journal of Investigative Dermatology (2013) 133, 589–592. doi:10.1038/jid.2012.427
Commentary
Serum 25-hydroxyvitamin D (25OHD)
levels reflect available body stores of
vitamin D obtained from UV exposure,
diet, and supplements. Circulating vita-
min D is hydroxylated in the liver to
25OHD, and then in kidneys or in other
cell types including keratinocytes, to
the active form, calcitriol (1,25(OH)2D).
Vitamin D–mediated gene transcription
influences calcium and phosphorus reg-
ulation, immune function, angiogenesis,
cellular growth, differentiation, and
apoptosis (Holick, 2007). In this issue,
van der Pols et al. (2013) report a posi-
tive association between baseline vita-
min D levels and basal cell carcinoma
(BCC) and melanoma incidence and a
negative association with squamous cell
carcinoma (SCC) incidence.
Serum vitamin D level and skin cancer
risks
The literature contains many reports of
associations between vitamin D levels
and chronic diseases and malignancies
(Reddy and Gilchrest, 2010). Anticar-
cinogenic and procarcinogenic actions
of vitamin D have also been discussed.
Although associations have been made
between low-normal vitamin D levels
and studied diseases, high-normal
vitamin D levels have also been asso-
ciated with disease, including prostate
and pancreatic cancers (Tuohimaa
et al., 2004; Stolzenberg-Solomon
et al., 2006). Associations between
vitamin D levels and risk of skin
cancer have been examined in several
studies (Asgari et al., 2010; Tang et al.,
2010, 2011; Eide et al., 2011; Lamberg
et al., 2011; Liang et al., 2012).
The study by van der Pols et al. (2013)
assesses the association between base-
line serum 25OHD levels and skin
cancer risk, as determined by prospec-
tive incidence of histologically con-
firmed skin cancer in 1,191 adults for
11 years after serum 25OHD measure-
ment at the end of winter. Odds ratios
(ORs) were adjusted for multiple factors,
including age, sex, personal or family
history of skin cancer, skin color, and
usual time spent outdoors. Recorded but
not included in the analysis were
vitamin D intake and supplement use,
number of nevi, skin aging, body
mass index, sunscreen use, physical
activity, presence of other medical con-
ditions, calcium intake, and smoking
status. Socioeconomic status was not
reported.
In subjects with a history of skin
cancer, 25OHD levels above 75 nmol/
L were associated with increased inci-
dence of BCC (OR 1.51, 95% confi-
dence interval (CI) 1.1–2.07, P¼ 0.01)
and melanoma (OR 2.71, 95% CI 0.98–
7.48, P¼0.05) and with reduced
incidence of SCC (OR 0.67, 95% CI
0.44–1.03, P¼0.07). Interestingly,
those who did not have a history of
skin cancer before baseline 25OHD
measurement did not show an associa-
tion of vitamin D level with skin cancer
risk. Vitamin D levels were highly cor-
related with self-reported time spent
outdoors in the 6 months preceding
serum 25OHD measurement and dur-
ing follow-up. Childhood or previous
adulthood sun exposure habits,
although likely influencing skin cancer
risk, were not examined. Those who
reported more than half of their time
spent outdoors had vitamin D levels
averaging 76 nmol/L, generally overlap-
ping with the group that displayed
higher risks for BCC and melanoma
and a lower risk for SCC.
Previous studies have found confirma-
tory and conflicting results (Table 1).
Most have had primarily female subjects
and have suggested that BCC and SCC
incidences increase with vitamin D
levels. The prospective Nurses’ Health
study found baseline 25OHD levels to
be associated with increased BCC (OR
2.07) and SCC (OR 3.77) incidences
when comparing 25OHD 478–85
witho50 nmol/L and adjusting for mul-
tiple factors (Liang et al., 2012). BCC
was associated with vitamin D levels
only when 25OHD samples collected
outside of summer were examined; van
der Pols et al. (2013) also used non-
summer 25OHD levels. Vitamin D
levels were similar at 3 and 10 years
in the Nurses’ Health Studies, suggesting
that baseline 25OHD measurements
were reasonable markers of long-term
25OHD levels (Kotsopoulos et al.,
2010). Sun exposure remains a likely
confounding factor in most studies, with
the authors concluding that 25OHD
levels likely reflect sun exposure
habits and therefore predict risk for
nonmelanoma skin cancer. A second
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prospective study in 3,233 low-bone-
density, white individuals, mostly
female, also found positive correla-
tions between baseline 25OHD levels
(437.5 nmol/L) and increased risk for
both BCC and SCC (OR 1.7–2.2), citing
sun exposure as a likely causative factor
(Eide et al., 2011). Asgari et al. (2010)
also found that vitamin D levels cor-
related with BCC risk (OR 2.09, 95%
CI 0.95–4.58, P¼ 0.11). In addition, a
large Danish study reported reduced
incidence of BCC, but not SCC, in those
with hip fracture histories (OR 0.90)
hypothesized to result from reduced
sun exposure (Lamberg et al., 2011).
One study in elderly men reported
contrary results from most other
studies, finding baseline 25OHD levels
475 nmol/L to be associated with de-
creased risk for nonmelanoma skin can-
cer (OR 0.53, P¼ 0.026, BCC or SCC
not separately specified) (Tang et al.,
2010). Subjects with skin cancers
diagnosed at or after 25OHD collec-
tion were included, leading the authors
to suggest that sun avoidance as a result
of skin cancer diagnosis could explain
the reduced skin cancer incidence.
With some similarity, van der Pols
et al. (2013) have reported a reduced
risk for SCC, although not statistically
significant, in those with a history of
skin cancer and vitamin D levels
475 nmol/L. It appears that postdia-
gnosis sun avoidance was a less likely
factor in the findings of van der Pols
et al., as sun exposure adjustments were
made. Together, evidence suggests that
vitamin D levels of 38–85 nmol/L may
be a marker for increased BCC risk in
susceptible individuals and are variably
associated with increased or decreased
SCC incidence.
In addition to an observed in-
creased risk for BCC, van der Pols
et al. (2013) also found 25OHD levels
475 nmol/L to be a marker of increased
melanoma incidence. Particular mela-
noma subtypes, depths, and patient out-
comes were not described. UV exposure
again represents a confounding factor.
Sunburn has been strongly associated
with increased melanoma risk, and
chronic or occupational UV exposures
are associated with increased head and
neck melanomas, although also with
reduced overall melanoma risk (OR
0.67) (Newton-Bishop et al., 2011).
Reported associations between vita-
min D level and melanoma prognosis
have been variable. A prospective study
of 17,000 NHANES subjects followed
for up to 12 years found no associa-
tion between 25OHD levels and mela-
noma mortality (Freedman et al., 2007).
However, in a small study, higher
25OHD levels at the time of mela-
noma diagnosis, although generally
below 75 nmol/L, were associated
with reduced Breslow thickness (mean
56 nmol/L in melanomas o0.75 mm)
and with independently reduced risks
for relapse and death (highest tertile
25OHD 461 nmol/L, hazard ratio
(HR) 0.79 for relapse-free survival per
20 nmol/L, P¼0.01) (Newton-Bishop
et al., 2009). A valuable large inter-
vention study, the Women’s Health
Initiative (WHI), found that post-
menopausal women with a history
of nonmelanoma skin cancer who
received 1,000 mg calcium and 400 IU
vitamin D daily displayed a 57%
reduced incidence (P¼ 0.04) of
melanoma.
Procarcinogenic and anticarcinogenic
effects of vitamin D on skin cancer
Several of the factors that affect serum
25OHD levels likely contribute to skin
cancer risk, including sun exposure
habits, latitude, diet, supplement intake,
age, body mass index, skin color, vita-
min D receptor (VDR) polymorphisms,
chronic diseases, and socioeconomic
status. Associations of vitamin D levels
with additional risk factors may also be
a contributing factor, including immu-
nosuppression, human papillomavirus
infection, and smoking. Sun exposure
remains the most suspicious confound-
ing or cofactor. Although investigators
have adjusted for multiple factors in
published studies, all major factors have
not been analyzed and the possibility of
complete and accurate adjustment for
these multiple complex factors remains
improbable.
Despite many confounding factors,
the interesting finding by van der
Pols et al. (2013) of reduced SCC
incidence in individuals with 25OHD
475 nmol/L and the findings of the
WHI reporting reduced melanoma inci-
dence in women with a history of
nonmelanoma skin cancer taking
400 IU vitamin D daily, encourage eva-
luation of the cellular effects of vitamin
D on skin carcinogenesis.
Keratinocytes are one of the few cell
types possessing both 1-a- and 25-
hydroxylase and are thus able to pro-
duce calcitriol locally (Lehmann et al.,
1999). Variations in serum 25OHD
levels within the normal range are not
known to result in variations in calcitriol
levels, and hence it remains uncertain
whether variations in normal serum
25OHD levels cause changes in
cellular calcitriol levels, VDR activa-
tion, or gene activity. Cutaneous VDR
activation appears generally to reduce
growth and proliferation through
upregulation of the MEK/ERK and PI3K/
Akt pathways, as well as of calbindin,
IGFBP, E-cadherin, and b3 integrin.
BCL2, IL1, IL12, TNF-a, IFN-g, EGFR,
and telomerase are downregulated
(Field and Newton-Bishop, 2011).
Mice lacking the VDR develop incre-
ased nonmelanoma skin cancers and
Clinical Implications
 Physiological and environmental factors associated with serum 25OHD
levels have roles in skin cancer risk.
 Variable associations are reported between vitamin D levels and basal cell
carcinoma (BCC), squamous cell carcinoma, and melanoma incidence.
 UV radiation contributes to skin carcinogenesis, and vitamin D levels
above 75 nmol/L may be associated with increased risks for BCC and
melanoma.
 Vitamin D levels in the range of 50–75 nmol/L appear to be appropriate for
those at risk for skin cancer based on available literature.
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Table 1. Serum vitamin D levels and skin cancer risk
Investigator Methods Population
Associated
25OHD
level
(nmol/L)
Reference
25OHD
level
(nmol/L)
BCC risk
(OR, 95%
CI)
SCC risk
(OR, 95%
CI)
Melanoma
risk (OR, 95%
CI)
Regression analysis
variables
Liang et al.
(2012)
Baseline serum 25OHD;
prospective incidence of
BCC, SCC; 8–19-year
follow-up
Nurses’ Health
Study, 4,641
women, no history
of skin cancer
before 25OHD
collection
478–85 o50 OR 2.071
(1.52–
2.80),
Po0.01
OR 3.77
(1.70–
8.36),
Po0.01
— Age, season, local UVB
index, lab batch, hair
color, skin pigmentation,
sunburn tendency and
number; sun exposure
not studied
Eide et al.
(2011)
Baseline serum 25OHD;
incidence of BCC, SCC;
mean 10-year follow-up
HMO, 90%
women, 3,233
white, low bone
density,
immunocompetent
subjects
X37.5 o37.5 OR 1.7
(1.0–2.9),
Po0.05
OR 1.7
(0.7–4.0),
P40.05
— Age, sex, season, NMSC
anatomic location;
smoking and BMI not
adjusted
Asgari et al.
(2010)
Baseline 25OHD; BCC
incidence; 4–21-year
follow-up
Northern California
HMO, 220 patients,
220 controls, 52%
male
X75 o25 OR 3.61
(1.00–
13.10),
P¼ 0.03
— — BMI, smoking,
education, sun exposure,
X-ray exposure, history
of skin cancer
Lamberg
et al. (2011)
Case–controls with hip
fracture history; BCC and
SCC prevalence
69,000 BCC
patients and 11,000
SCC patients, age
40þ , Danish
cancer registry
— — OR 0.90
(0.85–
0.94)
OR 1.07
(0.98–
1.17)
— Age, sex, chronic
disease, socioeconomic
status
Newton-
Bishop et al.
(2009)
25OHD level 3–6
months after melanoma
diagnosis; Breslow
thickness, relapse, and
death; median follow-up
4.7 years
Leeds Melanoma
Cohort; 872
subjects
461 p 41.3 — — Relapse-free
survival HR
0.57 (0.33–
0.97);
Mean 25OHD
56 vs. 49nmol/l
in MMo0.75
vs. 43 mm
depth,
P¼0.002
Age, sex, BMI, season,
VDR status, Townsend
score, tumor site,
Breslow thickness,
supplement use
Tang et al.
(2010)
Baseline serum 25OHD;
prospective incidence of
self-reported NMSC
(BCC, SCC not
separately specified); 5-
year follow-up
Osteoporotic
fractures study; 930
community-
dwelling white
men, age 465
years
475 o40 NMSC OR
0.53
(0.30–
0.93),
P¼ 0.026
NMSC OR
0.53
(0.30–
0.93),
P¼ 0.026
— Age, BMI, season,
latitude, physical
activity, smoking
Tang et al.
(2011)
Calcium and vitamin D
supplementation
(1,000 mg/400 IU daily);
prospective incidence of
BCC, SCC, melanoma;
mean 7-year follow-up
WHI study cohort;
36,282
postmenopausal
women; age 50–79
years
— — No
difference;
HR 1.02
(0.95–
1.07)
No
difference;
HR 1.02
(0.95–
1.07)
HR 0.432
(0.21–0.90),
P¼0.038
Age, geographic region,
physical activity,
smoking, education,
socioeconomic status,
nutrient intake
Freedman
et al. (2007)
Baseline serum 25OHD;
prospective cancer
mortality; up to 12-year
follow-up
NHANES study,
16,818 subjects
None
observed
— — — No difference
in melanoma
mortality
Sex, race, smoking, BMI,
latitude, physical activity
van der Pols
et al. (2013)
Baseline serum 25OHD;
prospective incidence;
11-year follow-up
Australian skin
cancer prevention
study cohort; 1,191
adult men and
women, mean age
54 years
475 p75 OR 1.513
(1.10–
2.07),
P¼ 0.01
OR 0.673
(0.44–
1.03),
P¼ 0.07
OR 2.713
(0.98–7.48),
P¼0.05
Age, sex, family history
of skin cancer, skin
color, usual time
outdoors; BCC and SCC
further adjusted for neck
elastosis, back freckling,
propensity to sunburn
Abbreviations: BCC, basal cell carcinoma; BMI, body mass index; CI, confidence interval; HMO, health maintenance organization; HR, hazard ratio; 25OHD,
25-hydroxyvitamin D; MM, malignant melanoma; NHANES, National Health and Nutrition Examination Survey; NMSC, nonmelanoma skin cancer; OR, odds
ratio; SCC, squamous cell carcinoma; VDR, vitamin D receptor; WHI, Women’s Health Initiative.
1In subjects with 25OHD collection in non-summer months.
2In subjects with a history of nonmelanoma skin cancer; subjects with a history of melanoma were excluded from the study.
3In subjects with a history of skin cancer.
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display reduced NF-kB and p53 expres-
sion (Field and Newton-Bishop, 2011).
Furthermore, VDR polymorphisms have
been associated with variations in
BCC, SCC, and melanoma risk (Kostner
et al., 2012). Vitamin D appears to
mitigate UV damage in vitro by
reducing cyclobutane pyrimidine dimer
(CPD) formation, improving CPD
repair, inducing antioxidant metallo-
thionein, and reducing UVB-induced
apoptosis. Antiproliferative effects have
been observed in some melanoma and
basal cell carcinoma lines (Tang et al.,
2011).
Vitamin D may also influence skin
cancer through effects on immune cells.
Calcitriol appears to suppress T helper
type 1 (Th1) and increase Th2 and regula-
tory T-cell responses, which may reduce
immune surveillance of skin cancer
(Bikle, 2011). However, innate immunity
is promoted, including Toll-like receptor
induction, which may improve anti-
cancer responses (Bikle, 2011).
Clinical recommendations
van der Pols et al. (2013) have con-
firmed previously observed positive
associations between vitamin D level
and BCC risk and have suggested a
positive association with melanoma
and negative association with SCC
incidence. Large and complex con-
founding factors limit clinically applic-
able conclusions on the cause of the
observed associations. Although anti-
carcinogenic and procarcinogenic
actions of vitamin D in skin have been
described, the ultimate balance of
effects of serum 25OHD concentra-
tions on skin cancer remains unknown.
Intervention studies are more likely than
association studies to identify opportuni-
ties for effective health interventions.
Clinical risk assessment, prevention
methods, or treatment modalities for
BCC or SCC appear unlikely to change
significantly on the basis of vitamin D
level. However, on the basis of the
positive effect of vitamin D supplemen-
tation in reducing melanoma incidence
in the WHI study, investigation into the
optimal serum 25OHD range for pre-
vention or treatment of melanoma
through intervention studies may pro-
vide information that can improve
clinical outcomes.
Current evidence suggests that it may
be prudent to avoid both vitamin D
deficiency (o25–50 nmol/L) and high-
normal vitamin D levels (475 nmol/L)
in patients at risk for skin cancer, parti-
cularly by avoiding excessive UV expo-
sures. Although van der Pols et al.
(2013) found that SCC incidence
reduced when 25OHD levels were
above 75 nmol/L, other studies have
found increased SCC risks, and these
levels have further been associated with
pancreatic and prostate cancers.
The recommendation by the Institute
of Medicine for serum 25OHD targets of
50–75 nmol/L appears prudent and is
supported by skin cancer association
studies (Ross et al., 2011). In addition,
modest vitamin D supplementation
(400 IU) may be beneficial in reducing
melanoma incidence in patients with a
history of nonmelanoma skin cancer.
Vitamin D levels have been associated
with both higher and lower rates of
disease depending on the disease
studied; therefore, overall health
should be considered when selecting a
serum vitamin D goal in the context of
skin cancer management. Because UV
exposure remains a well-known skin
carcinogen, oral calcitriol presents the
safest and most reliable supplemen-
tation method.
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